Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

Sponsor
Yehui Tan
Study ID
NCT06990321
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Acute Myeloid Leukemia (AML)
  • Elderly

Eligibility Criteria

Sex
ALL
Age
60 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the Elderly

Key Dates

Start date
Jun 1, 2025
Status verified
Aug 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
68 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Middle-and High-risk Acute Myeloid Leukemia in the Elderly

Primary Outcome Measure

Relapse-Free Survival(RFS) [ Time Frame: From date of index treatment to death, disease progression, or end of study, whichever came first, assessed up to 36 months. ]

Central Contacts

Related Studies